Single Treatment of Engineered Antibody Demonstrates 100 Percent Response Rate in Follicular Lymphoma

University of Pennsylvania Cancer Center
Ultima Vez Modificado:: 18 de mayo de 1998

Monoclonal antibodies are small proteins directed against ³marker proteins,² known as antigens, present on the surface of tumor cells. This antibody, known as Anti-B1 Antibody, is directed against CD-20 antigens present on follicular lymphoma cancer cells. Radioactive iodine (I-131) attached to the monoclonal antibody provides directed killing of the cells to which it attaches.

The researchers of this study presented results from a phase II trial of I-131 Anti-B1 Antibody, conducted with patients not previously treated for follicular lymphoma. The results were quite impressive, with an initial tumor response rate of 100 percent -- 71% complete response and 9% partial response -- in 21 patients. Treatment was generally well-tolerated. This therapy appears to be a promising new agent for first-line treatment of follicular lymphoma, though larger trials will be needed to determine its long-term benefit.

[ Original Abstract ]


A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Manténgase informado con las últimas informaciones de OncoLink!   Subscribe to OncoLink eNews
View our newsletter archives